These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 30279156)

  • 1. Question 1: Palivizumab for all children with Down syndrome?
    Huggard D; Molloy EJ
    Arch Dis Child; 2019 Jan; 104(1):94-97. PubMed ID: 30279156
    [No Abstract]   [Full Text] [Related]  

  • 2. Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan.
    Kashiwagi T; Okada Y; Nomoto K
    Paediatr Drugs; 2018 Feb; 20(1):97-104. PubMed ID: 28895096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palivizumab use in infants with Down syndrome-report from the German Synagis™ Registry 2009-2016.
    Simon A; Gehrmann S; Wagenpfeil G; Wagenpfeil S
    Eur J Pediatr; 2018 Jun; 177(6):903-911. PubMed ID: 29651734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Question 1: Do children with Down syndrome benefit from extra vaccinations?
    Huggard D; Molloy EJ
    Arch Dis Child; 2018 Nov; 103(11):1085-1087. PubMed ID: 30120141
    [No Abstract]   [Full Text] [Related]  

  • 5. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.
    Vogel AM; Lennon DR; Broadbent R; Byrnes CA; Grimwood K; Mildenhall L; Richardson V; Rowley S
    J Paediatr Child Health; 2002 Dec; 38(6):550-4. PubMed ID: 12410864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study.
    Yi H; Lanctôt KL; Bont L; Bloemers BL; Weijerman M; Broers C; Li A; Kiss A; Mitchell I; Paes B;
    Pediatrics; 2014 Jun; 133(6):1031-7. PubMed ID: 24799541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
    Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palivizumab use in preterm neonates.
    Kingston S; Murphy BP
    Ir Med J; 2010 May; 103(5):141-4. PubMed ID: 20666085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHD and respiratory syncytial virus: global expert exchange recommendations.
    Tulloh RMR; Medrano-Lopez C; Checchia PA; Stapper C; Sumitomo N; Gorenflo M; Jung Bae E; Juanico A; Gil-Jaurena JM; Wu MH; Farha T; Dodge-Khatami A; Tsang R; Notario G; Wegzyn C
    Cardiol Young; 2017 Oct; 27(8):1504-1521. PubMed ID: 28619123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).
    Wang DY; Li A; Paes B; Mitchell I; Lanctôt KL;
    Eur J Pediatr; 2017 Mar; 176(3):413-422. PubMed ID: 28105526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Where are we with RSV prophylaxis?
    Caldwell NA; Townsend C
    Arch Dis Child Educ Pract Ed; 2016 Feb; 101(1):38-42. PubMed ID: 26510447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab.
    Paes B; Mitchell I; Yi H; Li A; Lanctôt KL;
    Pediatr Infect Dis J; 2014 Feb; 33(2):e29-33. PubMed ID: 23989104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
    Warren A; Langley JM; Thomas W; Scott J
    Can J Cardiol; 2007 May; 23(6):463-6. PubMed ID: 17487291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden.
    Navér L; Eriksson M; Ewald U; Linde A; Lindroth M; Schollin J
    Acta Paediatr; 2004 Nov; 93(11):1470-3. PubMed ID: 15513574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of palivizumab in primary practice.
    Perrin KM; Bégué RE
    Pediatrics; 2012 Jan; 129(1):55-61. PubMed ID: 22184649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence over a period of 8 years of patterns of prescribing palivizumab for patients with and without congenitally malformed hearts, and in admissions to paediatric intensive care.
    Turner A; Begg C; Smith B; Coutts J
    Cardiol Young; 2009 Aug; 19(4):346-51. PubMed ID: 19476692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The European Forum for Clinical Management: prophylaxis against the respiratory syncytial virus in infants and young children with congenital cardiac disease.
    Tulloh RM; Feltes TF
    Cardiol Young; 2005 Jun; 15(3):274-8. PubMed ID: 15865829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palivizumab in congenital heart disease: should international guidelines be revised?
    Geskey JM; Thomas NJ; Brummel GL
    Expert Opin Biol Ther; 2007 Nov; 7(11):1615-20. PubMed ID: 17961086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of palivizumab in children with childhood interstitial lung disease: The French experience.
    Drummond D; Thumerelle C; Reix P; Fayon M; Epaud R; Clement A; Mahloul M; Habouria D; Delacourt C; Hadchouel A
    Pediatr Pulmonol; 2016 Jul; 51(7):688-95. PubMed ID: 26636747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.